Navigation Links
ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
Date:1/28/2010

f inflammation by means of its receptor (C5aR). This system is active in many diseases, thus making C5aR an attractive target for small molecule therapeutics.  Given molecular structure similarities between the C5aR and chemokine receptors, ChemoCentryx researchers successfully applied the Company's proprietary drug discovery technologies to the design of small molecule C5aR antagonists and selected CCX168 based on its potency, selectivity and favorable pharmacokinetics.  C5aR is one of four defined chemokine and chemoattractant receptor projects covered under an alliance between ChemoCentryx and GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).  

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. CCX025, also a CCR9 antagonist, has to date successfully completed a Phase I clinical program.  Additional clinical programs include CCX140, which targets the CCR2 receptor, expected to enter Phase II clinical development in the first quarter
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:12/20/2014)... -- The holidays can be anything but joyous for ... scented candles and other allergy triggers. "The dust ... been packed away in dank basements or dusty attics ... Dr. Rachna Shah, an affiliate faculty member at Loyola ... news release. Shah, who is also an allergist ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... 20, 2014 The Twin Cities DI ... event in the nation! Over 250 financial professionals come ... information on the industry, get motivated to protect their ... people facing and overcoming the challenges of disability. , ... the nation came together to attend The 13th Annual ...
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... There are now 75 clinical trials and 11 systematic reviews ... is slowing. How will we ever cope?, ask Hilda Bastian, ... PLoS Medicine , who also decry the continued poor quality ... growth of reviews of evidence, the authors recommend that we ...
... PORTLAND, Ore - Research conducted at Oregon Health & ... debate about the risks associated with administering a specific ... is published in the current edition of Cell ... led by institute director Jay Nelson, Ph.D., studies human ...
... Ill. September 21, 2010 Researchers from Italy ... follow-up showing that the placement of multiple endoscopic stents ... with a low rate of stricture recurrence after this ... can be safely and successfully retreated endoscopically. The study ...
... resource guide for internists on the health care reform ... Affordable Care Act (PPACA), was released today by the ... Guide to Understanding Health System Reform was developed by ... significant player in helping to shape the health care ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay News) ... the blood thinner Plavix with proton-pump inhibitors like Nexium, ... Plavix,s effectiveness. "We looked into this highly debated ... researcher Dr. Mette Charlot from the department of cardiology ...
... One hundred and sixty-six years after Samuel Morse used ... opening up a whole new world of communication, Indiana ... use a potentially equally revolutionary tool, the Nationwide Health ... U.S. Centers for Disease Control and Prevention (CDC). ...
Cached Medicine News:Health News:OHSU research suggests compound administered during some bone marrow transplants elevates risks 2Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 2Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 3Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 4Health News:Updated resource guide for internists released by ACP 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:Nationwide Health Information Network now carries public health data 2Health News:Nationwide Health Information Network now carries public health data 3
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required....
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #2...
Medicine Products: